Mikhail Blagosklonny’s Achievements in the Field of Oncology

Mikhail Blagosklonny is a prominent scientist and researcher who has gained a strong reputation in performing studies on aging and cancer. Dr. Blagosklonny is a professor at Roswell Park Cancer Institute where he teaches oncology. Mikhail holds a Ph.D. in cardiology and experimental medicine and a master’s degree in internal medicine from the First Pavlov State Medical University of St. Peterburg. He started his career as an associate professor of medicine at the New York Medical College in Valhalla. After working as an associate professor, he joined the Roswell Park Cancer Institute in 2009 where he is responsible for teaching and conducting research in the field of oncology.

Research Work

Mikhail Blagosklonny has a long-time interest in researching cancer, targeting cancer therapies that keep healthy cells from being damaged by radioactive rays and chemotherapy, anti-aging treatments and biogerontology (the mechanism of aging). Other research areas include molecular and cellular biology and clinical investigations. Additionally, he has made several clinical investigations on tumor and oncogenes suppressors, cell cycle, signal transduction, apoptosis, mitosis and anticancer therapeutics. His research has enabled him to identify potential compounds that slow down the aging process, inventing essential anti-aging drugs like rapamycin.

Mikhail’s hypothesis: Role of TOR Signaling in Cancer and Aging

Blagosklonny has made a lot of progress in his research on aging, and a good example is a theory he unveiled on the possible role of TOR in cancer and aging. In this hypothesis, Mikhail says that aging is subject to genetic influence in model organisms. Over time, aging causes non-random organ damage like renal failure, stroke, and infarction, just to name a few and finally death. View Mikhail’s profile on Google Scholar

TOR (Target of Rapamycin) is a mitogen- and nutrient-sensing signaling pathway that stimulates growth. The TOR incorporates signals from changes in energy status, growth factors, nutrient availability and different physiological stresses. TOR then relays the signal to outputs to suitably respond to such environmental changes.

Editorial activities

The renowned scientist and researcher is the editor-in-chief of Oncotarget on Nature and Aging, Cell Cycle. He is also a member of the editorial board of Cell Death and Differentiation as well as an associate editor of Cancer Biology and Therapy.

Additionally, Mikhail has published more than 270 papers in peer-reviewed journals. The journals have earned him an h-index of 83 since they have more than 25,000 references. Visit ResearchGate to know more about Mikhail’s latest work.

Capitol Anesthesiology Investments

The medical field has had a lot of changes in recent years. As a company, Capitol Anesthesiology has invested a lot of money to be on the front end of these changes. If you want to invest in your future, you should follow their example. Despite being in an industry that is constantly changing, Capitol Anesthesiology is on the front end of this research. This is why people from all over the country come down to Austin to visit with people who work there.

Capitol Anesthesiology

They do a great job of helping customers with all of their medical needs. Not only that, but they sincerely care about the future of the medical industry as well. With all of the community service that this company is a part of, it is no wonder that they are thought so highly of around the country.